Market Overview

UPDATE: JP Morgan Upgrades Teva Pharmaceuticals

Related TEVA
Mesoblast's Delayed Launches, Teva Split Turn Credit Suisse Bearish
Height Casts 65% Odds That Congress Rolls Back Pharma Discounts
Teva launches generic Aloxi in U.S. (Seeking Alpha)

On Friday, JP Morgan upgraded shares of Teva Pharmaceuticals (NYSE: TEVA) from Underweight to Neutral and raised the profit target to $49.

Analyst Chris Schott is encouraged by “favorable initial Copaxone 3x weekly trends and the potential for additional cost cutting activity,” but remains “less enthusiastic around Teva's organic growth prospects and its P&L reliance on Copaxone.”

Schott expects Teva management's “willingness to consider larger business development opportunities will be well received.”

Shares of Teva are up 21 percent year-to-date and up 1.8 percent to $48.82 during Friday's session.

Latest Ratings for TEVA

Feb 2018Credit SuisseMaintainsOutperformOutperform
Feb 2018Credit SuisseUpgradesNeutralOutperform
Feb 2018Bank of AmericaMaintainsUnderperformUnderperform

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Chris Schott JP MorganAnalyst Color Analyst Ratings


Related Articles (TEVA)

View Comments and Join the Discussion!